# Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

> **NCT03043313** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 117 (actual)

## Conditions studied

- Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT03043313
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-23
- **Primary completion:** 2022-03-28
- **Final completion:** 2023-11-02
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03043313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03043313, "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03043313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*